News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva product …
This article analyzes Innoviva Inc. (NASDAQ: INVA) using AI models, identifying divergent sentiment across time horizons and suggesting choppy market conditions. It provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance …
H.C. Wainwright reiterated a Buy rating and a $46 price target for Innoviva (NASDAQ:INVA) after the company surpassed second-quarter revenue forecasts. Despite a reported net loss of $108 million due to investment value changes, the firm raised its full-year 2026 revenue forecast while maintaining …
Argus has lowered its target price for Innoviva Inc. (INVA) to $23.00, according to a report published on August 5, 2026. Innoviva Inc. is described as a company holding a portfolio of royalties in healthcare assets, including a royalty portfolio, operating assets in critical …
Innoviva, Inc. reported a Q2 2026 net loss of US$83.42 million despite increased revenue, leading to a loss per share of US$1.14 from continuing operations. This quarterly loss contrasts with strong first-half net income, creating a volatile earnings picture. The company's recent US$66.40 million …
Innoviva (INVA) stock saw a 2.9% increase despite a significant Q2 2026 profit reversal, swinging from a profit of US$63.7 million to a loss of US$83.4 million. The company's revenue, however, grew by 19% to US$119.6 million, driven by its Specialty Therapeutics portfolio and …
Innoviva, Inc. reported mixed Q2 2026 results with increased revenue but a swing from net income to a significant net loss, while also completing a substantial share repurchase. This financial performance and capital allocation strategy may prompt investors to re-evaluate the company's investment narrative, …
This article provides current stock information for Innoviva Inc (INVA), including its stock price, market cap, and P/E TTM. It indicates that further news, earnings reports, analyst ratings, and key developments are anticipated to be published soon on the platform. The page primarily serves …
Innoviva, Inc. (NASDAQ: INVA) announced strong second-quarter 2026 financial results, driven by robust performance from its royalty portfolio and significant growth in Innoviva Specialty Therapeutics (IST) net product sales. The company achieved 19% year-on-year total revenue growth to $119.6 million and saw IST U.S. …
Innoviva (INVA) reported Q2 earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.56, and revenues of $119.59 million, also surpassing estimates by 5.63%. Despite outperforming estimates four times over the past year, the stock currently holds a Zacks Rank #5 (Strong …
Innoviva, Inc. reported its Q2 revenue of $119.6 million, surpassing the FactSet estimate of $111.0 million. The company, a diversified holding company with a focus on healthcare assets and royalties from respiratory products, also announced an update on its equity buyback plan. Innoviva's product …
First Trust Advisors LP significantly increased its stake in Innoviva, Inc. by 134.6% in Q1, now holding 278,340 shares valued at approximately $6.5 million. Other institutional investors also adjusted their holdings, with overall institutional ownership at 99.12%. Innoviva's Q1 EPS beat analyst estimates, while …
Healthcare of Ontario Pension Plan Trust Fund significantly reduced its stake in Innoviva, Inc. (NASDAQ:INVA) by 79.4% in the first quarter, selling over 262,000 shares. Despite this sell-off, institutional ownership remains high at 99.12%, with other investors increasing their positions. Analysts generally maintain a …
Innoviva, Inc. (NASDAQ:INVA) generated a total revenue of $411.33 million USD last year. The Respiratory Products segment was its top-performing segment, contributing the entirety of this revenue. The largest geographical contribution to the company's revenue came from Great Britain.
This article provides a bond profile for THRX5561968, an Innoviva, Inc. bond with a 2.125% coupon maturing on March 15, 2028. It details key facts such as the issue date, outstanding amount, face value, and a description of Innoviva, Inc. and its biopharmaceutical activities.
This article provides a coupon profile for the Innoviva, Inc. 2.125% 15-MAR-2028 bond (THRX5561968). It details the current coupon rate of 2.13% and highlights that the next interest payment is scheduled for September 15, 2026. The piece also mentions that more in-depth coupon data, …
Vanguard Capital Management LLC, along with its affiliates, has filed a Schedule 13G, disclosing beneficial ownership of 3,704,185 shares of Innoviva Inc (INVA) common stock, which represents a 5.01% stake in the company. Vanguard reports sole voting power over 546,132 shares and sole dispositive …
This article analyzes Innoviva Inc. (NASDAQ: INVA) volatility, highlighting divergent sentiment across all time horizons and elevated downside risk. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal …
The article provides a risk assessment for Innoviva Inc (INVA), indicating a current risk assessment score of 7.78, ranking it 34 out of 155 in the Pharmaceuticals industry. The company's beta is 0.36, suggesting it tends to underperform in up markets but has smaller …
The article analyzes the financial health of Innoviva Inc (INVA), highlighting its robust status and high operating efficiency with a current financial score of 8.99. The company's latest quarterly revenue increased by 10.56% year-over-year, and net profit saw a significant increase of 500.56% year-over-year. …
Innoviva Inc (INVA) has a current valuation score of 8.20, ranking 102 out of 155 in the Pharmaceuticals industry. The company's P/E ratio stands at 2.92, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, …
This article provides a detailed cash flow statement for Innoviva Inc (INVA), covering quarterly and annual data for operating, investing, and financing activities. It presents key financial metrics such as net income, operating gains/losses, deferred tax, and changes in working capital over several fiscal …
The Thai Food and Drug Administration (FDA) has approved Nuzolvence (zoliflodacin), an oral antibiotic developed by Dr Reddy’s Laboratories for uncomplicated urogenital gonorrhoea. This approval marks a significant step in providing an innovative treatment, especially for multidrug-resistant strains, following a public-private R&D partnership with …
Innoviva, Inc. (DUS:HVE) generated 350.21 million EUR in revenue last year, primarily from its Respiratory Products segment. The largest contribution to revenue came from Great Britain, accounting for 201.34 million EUR. This financial overview details the company's top-performing segments and regional contributions.
Innoviva Inc (INVA) closed at $21.440, up 1.13%, with a market cap of $1.58 billion. The company has strong fundamentals, high growth potential, and is considered fairly valued by analysts, who largely rate it as a "Buy" with a target price of $35.50. Innoviva …
This article analyzes Innoviva Inc. (INVA) using AI models to determine its impact on rotational strategy timing. It highlights divergent sentiment, support/resistance levels, and presents three trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes …
Search by ticker symbol or company name and select a result to open its chart.